Back to Search
Start Over
Latest advances in the reversal strategies for direct oral anticoagulants.
- Source :
-
Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2024 Aug; Vol. 38 (4), pp. 674-684. Date of Electronic Publication: 2024 Feb 13. - Publication Year :
- 2024
-
Abstract
- Background: Since the late 2000s, Europe has granted approval for various thrombotic risk-related uses of direct oral anticoagulants (DOACs). Unlike traditional anticoagulants, DOACs do not necessitate routine coagulation monitoring. Nevertheless, clinical practice often encounters bleeding events associated with these medications, making the need for effective reversal strategies evident.<br />Objectives: The study aims to take stock of current reversal strategies for DOACs, with a particular emphasis on the latest compounds that have been developed or are currently under development.<br />Methods: For obtaining information regarding the ongoing reversal strategies and the compounds under development, we referred to ClinicalTrials website, PubMed, and Google Scholar.<br />Results: In 2024, two specific antidotes to DOACs have already received approval when reversal of anticoagulation is needed owing to life-threatening or uncontrolled bleeding: idarucizumab that reverses the effects of dabigatran, and andexanet alfa, designed to counteract activated factor X inhibitors such as apixaban and rivaroxaban. Furthermore, ciraparantag, a potential universal reversal agent, is currently in advanced stages of clinical development. Concerns remain regarding the safety of specific reversal agents, especially concerning the risk of thrombosis. Additionally, the cost of these antidotes remains high. Consequently, nonspecific strategies to counteract anticoagulant medications, including activated charcoal, hemodialysis, and concentrates of coagulation factors, still have utility.<br />Conclusion: With the validation of specific and nonspecific antidotes, DOACs could supplant traditional oral anticoagulants. This progress represents a significant advancement in anticoagulation therapy. However, ongoing research is crucial to address remaining safety concerns of the specific reversion agents of DOACs in clinical practice.<br /> (© 2024 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.)
- Subjects :
- Humans
Administration, Oral
Thrombosis prevention & control
Antibodies, Monoclonal, Humanized administration & dosage
Antibodies, Monoclonal, Humanized therapeutic use
Antibodies, Monoclonal, Humanized pharmacology
Antibodies, Monoclonal, Humanized adverse effects
Factor Xa Inhibitors adverse effects
Factor Xa Inhibitors administration & dosage
Factor Xa Inhibitors pharmacology
Recombinant Proteins administration & dosage
Factor Xa
Anticoagulants adverse effects
Anticoagulants administration & dosage
Anticoagulants pharmacology
Anticoagulants therapeutic use
Antidotes therapeutic use
Antidotes administration & dosage
Hemorrhage chemically induced
Subjects
Details
- Language :
- English
- ISSN :
- 1472-8206
- Volume :
- 38
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Fundamental & clinical pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38350629
- Full Text :
- https://doi.org/10.1111/fcp.12992